Topic:

Partnering

Latest Headlines

Latest Headlines

South Korea's Green Cross teams with Russia's Nanolek on biologics manufacturing

South Korea's Green Cross said it has signed an agreement with Nanolek, a Russia biopharmaceutical company, to produce its biologics in a three-month-old facility said to be state-of-the-art.

3-D printer Materialise partners with R&D house Kapstone to support medical device innovation

Kapstone Medical has partnered with high-profile 3-D printer Materialise to launch a service specifically for medical device entrepreneurs.

Big Pharma joins the U.K.'s genomics project with eyes on drug discovery

A group of the world's leading drugmakers have joined the U.K.'s ambitious initiative to sequence the genomes of 100,000 Britons, mining the data with hopes of finding new pathways to treat cancer and rare diseases.

Emergent BioSolutions nabs government funds to test new-and-improved anthrax vaccine

In a $31 million development agreement with Emergent BioSolutions announced Monday, the Department of Health and Human Services said it will fund Phase III development for NuThrax, Emergent's new anthrax vaccine that's already been funded through Phase I and II by the NIH and the Department of Defense.

Recipharm pairs up with Adroit for chemistry services

Contract drug developer Recipharm has inked a deal with Adroit Science to join forces in drug formulation.

Are jeans and cash the biotech success formula for Asia?

If there is a formula for how to be creative in the biotech industry in Asia, it probably doesn't include ingredients like getting the dress code relaxed and walls of cash as far as the eye can see for basic research.

Ranbaxy set to disappear from Indian stock exchanges

In one of its first acts as India's new leading drugmaker, Sun Pharmaceuticals announced the beginning of the end of Ranbaxy Laboratories by removing the company from the stock markets after trading has ended on April 1.

AstraZeneca buys into Harvard's stem cell tech for diabetes R&D

Harvard professor Doug Melton is having quite a week. His work on potential cell therapies for diabetes just fueled the launch of a well-funded biotech startup, and now he's signed up with AstraZeneca to help the drugmaker spotlight new treatments for the disease.

GE Healthcare's pathology arm to use Omnyx's software for digital analysis of specimens

GE Healthcare announced that its diagnostic laboratory company, Clarient, will soon deploy Omnyx's proprietary software, as pathology pivots away from visual diagnosis and toward quantitative computer-based tools.

ImmunoGen strikes $440M ADC deal with Takeda

ImmunoGen has struck a $440 million antibody-drug conjugate licensing deal with Takeda, moving it a step closer to recovering from the body blow of last year's Phase III flop. The heavily backloaded deal was cheered by investors.